Site-specific insulin-polymer conjugates

• US 9,789,196 B2
• Filed: 04/21/2015
• Issued: 10/17/2017
• Est. Priority Date: 04/11/2003
• Status: Expired due to Fees

• Current Assignee: Rezolute, Inc.
• Original Assignee: AntriaBio, Inc.
• Inventors: Hinds, Kenneth, Lewis, Danny, Schmidt, Paul, Campbell, Kathleen M.
• Primary Examiner(s): Robinson, Hope
• Application Number:
  US14/691,855
• Publication Number:
  US 20150216995A1
• Time in Patent Office: 910 Days
• Field of Search: None
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/62 Insulins

Abstract

The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.

Claims

1. An insulin-PEG conjugate comprising PEG linked to insulin at the PheB1 amino terminus via a secondary amine, wherein the conjugate comprises an unreacted GlyA1 amino terminus and an unreacted LysB29 amino terminus, wherein the insulin comprises human insulin having the amino acid sequence of SEQ ID NO:

1, and wherein the insulin retains insulin activity.

2. The insulin-PEG conjugate of claim 1, wherein the PEG comprises an amino-reactive PEG derivative selected from the group consisting of an aldehyde, a N-hydroxy succinimide, a PNP-carbonate, and a benzotrizole terminated hydrophilic polymer.

3. The insulin-PEG conjugate of claim 1, wherein the PEG is a linear polymer.

4. The insulin-PEG conjugate of claim 1, wherein the PEG is a branched polymer.

5. The insulin-PEG conjugate of claim 1, wherein the PEG has a molecular weight in the range of 500 to 50,000 Da.

6. The insulin-PEG conjugate of claim 1, wherein the PEG is a mPEG succinimidyl active ester of a propionic acid linker mPEG-SPA.

7. The insulin-PEG conjugate of claim 1, wherein the PEG is monomethoxy PEG-aldehyde.

18. The insulin-PEG conjugate of claim 1, wherein the insulin is native human insulin, and the PEG is monomethoxy PEG aldehyde.

8. A poly(lactide-co-glycolide) (PLGA) microsphere encapsulating an insulin-PEG conjugate, wherein the insulin-PEG conjugate comprises PEG linked to insulin at the PheBl amino terminus via a secondary amine, wherein the insulin comprises human insulin having the amino acid sequence of SEQ ID NO:

1, and wherein the insulin retains insulin activity.

9. An insulin-PEG conjugate produced according to a method comprising:

contacting insulin with PEG in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the insulin and PEG, wherein the formation of the insulin-PEG conjugate is by a predominant reaction of insulin at residue PheBl without protecting insulin at GlyAl and LysB29 residues; and

isolating the conjugate, wherein the insulin comprises human insulin having the amino acid sequence of SEQ ID NO;

1, and wherein the insulin retains insulin activity.

10. The insulin-PEG conjugate of claim 9, wherein the at least one organic solvent is selected from the group consisting of ethanol, methanol, DMSO, dioxane, DMF, and NMP.

11. The insulin-PEG conjugate of claim 9, wherein the at least one metal chelator is selected from the group consisting of a metal ion chelator, EDTA, deferoxamine (DEF), diethylenetriamine pentaacetic acid (DTPA), and bis(aminoethyl)glycolether N,N,N′

N′

-tetraacetic acid (EGTA).

12. The insulin-PEG conjugate of claim 9, wherein the insulin and the PEG are contacted at a pH from about 5.0 to about 7.5.

13. A F5000 insulin-PEG conjugate comprising PEG linked to insulin at the PheBl amino terminus via a secondary amine, wherein the insulin comprises human insulin having the amino acid sequence of SEQ ID NO:

1, and wherein the insulin retains insulin activity.

14. The F5000 insulin-PEG conjugate of claim 13, wherein the insulin-PEG conjugate is encapsulated by a biodegradable polymer microsphere.

15. The F5000 insulin-PEG conjugate of claim 14, wherein the biodegradable polymer comprises a poly(lactide), poly(glycolide), poly(d, l-lactide-co-glycolide), poly(caprolactone), poly(orthoester), copolymer of a poly(ester) and a poly(ether), or copolymer of a poly(lactide) and a poly(ethylene glycol).

16. The F5000 insulin-PEG conjugate of claim 14, wherein the biodegradable polymer is poly(lactide-co-glycolide).

17. A composition for preparing a pharmaceutical formulation, the composition comprising:

an organic solvent;

a metal chelator;

a first mono-PEGylated insulin conjugate comprising PEG linked to insulin at the PheBl amino terminus via a secondary amine;

a second mono-PEGylated insulin conjugate comprising PEG linked to insulin at either the GlyAl amino terminus or the LysB29 amino terminus;

an unreacted insulin protein; and

a di-PEGylated insulin conjugate, wherein;

the first mono-PEGylated insulin conjugate comprises 95% or greater of the total of the first mono-PEGylated insulin conjugate and the second mono-PEGylated insulin conjugate, wherein the insulin comprises human insulin having the amino acid sequence of SEQ ID NO;

1, and wherein the insulin retains insulin activity.